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A 12-Month Single Arm Pilot Study to Evaluate the Efficacy and 
Safety of Sirolimus in Combination with Tacrolimus in Kidney 
Transplant Recipients at High Immunologic Risk
The optimal immunosuppressive strategy for renal transplant recipients at high 
immunologic risk remains a topic of investigation. This prospective single arm pilot study 
was undertaken to evaluate the safety and efficacy of a combined tacrolimus and sirolimus 
regimen in recipients at immunological high risk and to compare outcomes with a 
contemporaneous control group received tacrolimus and mycophenolate mofetil. Patients 
that received a renal allograft between 2010 and 2011 at high risk (defined as panel 
reactive antibodies > 50%, 4 or more human leukocyte antigen mismatches, or 
retransplantation) were enrolled. All patients received basiliximab induction and 
corticosteroids. A total of 28 recipients treated with tacrolimus and sirolimus were enrolled 
in this study and 69 recipients were retrospectively reviewed as a control group. The 
sirolimus group showed a higher, but not statistically significant, incidence of biopsy 
proven acute rejection and a lower glomerular filtration rate than the control group. 
Furthermore, sirolimus group was associated with significant increases in BKV infection  
(P = 0.031), dyslipidemia (P = 0.004), and lymphocele (P = 0.020). The study was 
terminated prematurely due to a high incidence of adverse events. A de novo tacrolimus/
sirolimus combination regimen may not be an ideal choice for recipients at high 
immunological risk.
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INTRODUCTION
Recent immunosuppressive agent developments and patient 
management improvements have increased overall early graft 
survival after renal transplantation. However, certain subpopu-
lations with a high titer of panel reactive antibodies (PRAs), four 
or more human leucocyte antigen (HLA) mismatches, or a his-
tory of previous allograft loss remain at high risk of acute rejec-
tion and allograft loss (1). To reduce acute rejection rates, clini-
cians have tried to maintain high concentrations of immuno-
suppressants (2, 3), but optimal drug levels for patients at high 
immunological risk have not been clearly defined. Furthermore, 
the nephrotoxic effects of calcineurin inhibitors (CNIs) contrib-
ute to progressive graft dysfunction and diminish long-term graft 
survival (4, 5). 
 Sirolimus is a macrocyclic lactone antibiotic produced from 
Streptomyces hygroscopicus and a potent immunosuppressive 
agent with a multifaceted action mechanism quite distinct from 
that of CNIs. Sirolimus forms a complex with FKBP-12, which 
binds to the mammalian target of rapamycin (mTOR), and thus, 
inhibits cytokine-induced signal transduction pathways and 
arrests the cell cycle (6). Furthermore, early preclinical experi-
ence indicates that the sirolimus-tacrolimus combination ex-
hibits immunosuppressive synergy (7). 
 In an attempt to reduce acute rejection and minimize the tox-
icity of tacrolimus, several authors have investigated the use of 
tacrolimus and sirolimus in combination (8-10). We designed 
this study to assess the clinical safety and efficacy of a tacrolimus/ 
sirolimus regimen in renal allograft recipients at high immuno-
logical risk.  
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MATERIALS AND METHODS
Inclusion criteria
Adult patients (> 18 yr) with end stage renal disease scheduled 
to receive renal transplantation and at high immunological risk 
(defined as a PRA > 50% during the previous 6 months, 4 or more 
HLA mismatches, or a history of previous graft loss) were eligi-
ble for enrollment. The retrospective contemporaneous control 
group also consisted of patients at high immunological risk.
Immunosuppression
All patients received 20 mg basiliximab on day 0 and 4 after trans-
plantation. The initial dose of methylprednisolone (500-1,000 
mg) was tapered to oral prednisolone (5-10 mg/day). Patients 
with a high PRA (having a PRA > 50%) received one dose (375 
mg/m2) of rituximab two days prior to transplantation.
Sirolimus group
Initial tacrolimus was administered orally at 0.1 mg/kg twice 
daily. Subsequent doses were adjusted to maintain a whole blood 
trough concentration from 10 to 15 ng/mL between days 1 and 
14 post-transplantation, from 5 to 10 ng/mL between days 15 
and 180, and from 3 to 7 ng/mL between days 181 and 360.
 Sirolimus was started with a 6mg loading dose on day 3, and 
then reduced to maintain a whole blood trough concentration 
(as determined by an antibody conjugated magnetic immuno-
assay) of 5-10 ng/mL until day 14 and of 10-15 ng/mL between 
days 15 and 360.
Contemporaneous control group
These patients were managed by triple drug immunosuppres-
sion consisting of tacrolimus, mycophenolate mofetil (MMF), 
and corticosteroids. Target trough concentrations of tacrolimus 
were similar to those in the sirolimus group (5-10 ng/mL until 
day 180, and 3-7 ng/mL between day 181 and 360). 
Endpoints
The study efficacy variables were the incidence of biopsy prov-
en acute rejection (BPAR) and estimated glomerular filtration 
rates (eGFR) at 6 and 12 months. BPAR events were classified 
using the Banff 2007 classification. Safety variables included 
the incidences of specific adverse events of particular interest 
(viral infections, pneumonitis, new onset diabetes mellitus, dys-
lipidemia, lymphocele, wound complications, and malignancy) 
and of adverse events leading to study discontinuation. A pre-
defined acceptable serious adverse events threshold of 50% was 
implemented. 
Crossmatch
HLA crossmatch was determined using a complement-depen-
dent lymphocytotoxicity (CDC) assay. The NIH (National Insti-
tute of Health) and AHG (anti-human globulin)-enhanced CDC 
(complement-dependent cytotoxicity) assays were performed 
to detect antibodies against donor T cells. The CDC assay was 
used to detect warm antibodies against B cells
 Panel reactive HLA IgG antibodies (PRA) were identified by 
LIFECODES Class I and Class II ID assay kits (Tepnel Lifecodes 
Molecular Diagnostics, Stamford, CT, USA), which utilize the 
multiplex bead-based immunoassay principle.
Statistical analysis
Demographic and background information was summarized 
using frequency counts (percentages) for categorical variables, 
and using descriptive statistics, that is, means, standard devia-
tions, medians, minima, and maxima for continuous variables. 
Efficacy and safety analyses were conducted according to the 
intention to treat (ITT) principle and included all patients that 
received at least one dose of the study regimen (tacrolimus plus 
sirolimus or MMF). The student’s t-test was used to determine 
the significances of differences between the means of numeri-
cal variables in the sirolimus and control groups. The chi-square 
test with Fisher’s exact test was used to compare nominal vari-
ables. P values less than 0.05 were considered statistically sig-
nificant, and the analysis was performed using SPSS software 
(version 20.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
This prospective, 12-month, open-labeled, single arm pilot study 
was approved by the institutional review board of Severance Hos-
pital, Yonsei University Health System (4-2009-0294). Informed 
consent was waived by the board. 
RESULTS
A total of 28 patients were enrolled, and these were compared 
with a contemporaneous control group consisting of 69 recipi-
ents. Initially, we planned to recruit 50 recipients, but because 
of efficacy and safety concerns, our data and safety monitoring 
board recommended discontinuation of further enrollment. This 
pilot study was stopped prematurely, but 20 patients (71.4%) 
completed the study on protocol drugs.
 Demographic and baseline characteristics are summarized 
in Table 1. No statistical differences were observed between the 
sirolimus and control groups in terms of recipient, donor, or 
immunologic factors, with the exception of mean number of 
HLA-DR mismatches and deceased donor proportion, which 
was significantly higher in the control group. However, there 
were no significant differences between re-transplantation, high 
PRA titer, or total number of HLA mismatches. Donor-specific 
anti-HLA antibodies were not routinely assessed during the study 
period. Mean serum tacrolimus and sirolimus concentrations 
during the study period are provided in Fig. 1.
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Table 1. Patient demographics
Factors
Sirolimus group 
(n = 28)
Control group 
(n = 69)
P value
Recipient factors
   Age (yr)
   Male recipients
47.71 ± 9.01
12 (42.9%)
44.94 ± 10.76
38 (55.1%)
0.232
0.275
Donor factors
   Deceased donor
   Donor age (yr)
   Male donors
4 (14.3%)
44.96 ± 10.90
12 (42.9%)
33 (47.8%)
43.43 ± 12.31
35 (50.7%)
0.002
0.569
0.482
Immunologic factors
   Previous renal transplant
   High PRA 
   HLA-mismatch
      A
      B
      DR
   Total HLA mismatch ≥ 4
  6 (21.4%)
14 (50.0%)
3.89 ± 1.45
1.07 ± 0.72
1.43 ± 0.63
1.39 ± 0.57
18 (64.3%)
  8 (11.6%)
27 (39.1%)
3.59 ± 1.44
1.03 ± 0.69
1.46 ± 0.68
1.10 ± 0.67
50 (72.5%)
0.219
0.326
0.357
0.786
0.814
0.045
0.425
PRA, panel reactive antibody; HLA, human leukocyte antigen.
Table 2. Efficacy and safety results 
Parameters
Sirolimus group 
(n = 28)
Control group 
(n = 69)
P value
Renal function
   6 month eGFR (mL/min/1.73 m2)
   12 month eGFR (mL/min/1.73 m2)
47.4 ± 19.7
48.4 ± 22.6
53.8 ± 19.0
56.2 ± 19.2
0.148
0.094
Biopsy proven acute rejection 9 (32.1%) 18 (26.1%) 0.546
Graft loss 2 (7.1%) 1 (1.4%) 0.199
Patient death 1 (3.6%) 0 0.289
Delayed graft function 3 (10.7%) 11 (15.9%) 0.751
Viral infection
   BKV infection
      BK viremia
      BKV nephropathy 
   CMV infection
7 (25.0%)
7 (25.0%)
4 (14.3%)
1 (3.6%)
6 (8.7%)
6 (8.7%)
1 (1.4%)
6 (8.7%)
0.031
0.669
Pneumonitis 2 (7.1%) 0 0.081
New-onset diabetes mellitus 7 (25.0%) 9 (13.0%) 0.225
Dyslipidemia 22 (78.6%) 32 (46.4%) 0.004
Lymphocele 5 (17.9%) 2 (2.9%) 0.020
Wound complication 2 (7.1%) 2 (2.9%) 0.577
Malignancy 0 1 (1.4%) > 0.99
eGFR, estimated glomerular filtration rate (MDRD, modification of diet in renal disease 
formula); TCMR, T cell mediated rejection; CMV, cytomegalovirus.
Fig. 1. Mean study drug trough levels by visit window. (A) Tacrolimus, (B) Sirolimus; 
mean values with±standard deviations at each time point. The dashed lines repre-
sent the respective target trough levels, (C) Mean tacrolimus trough levels of sirolim-
us group and control group.
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 In sirolimus group (n = 28), 8 patients (28.6%) were withdrawn 
from the study from the study. Mean time to discontinuation 
was 74.3 days. Four discontinued because of rejection, two for 
infection, one for drug-induced pneumonitis, and one for car-
diac arrest. Most patients who discontinued assigned therapies 
were switched to tacrolimus and MMF.
 Efficacy and safety results are summarized in Table 2. Renal 
function was assessed using mean estimated glomerular filtra-
tion rate (eGFR, calculated using the modification of diet in re-
nal disease formula). Mean eGFR of the control group was high-
er than in the sirolimus group at the time points, but this was 
not statistically significant. Overall rejection rates were similar 
in the two groups (32.1% in the sirolimus group, 26.1% in the 
control group, P = 0.546). The anti-rejection treatments and re-
sponses to treatment are summarized in Table 3. In the sirolim-
us group, two recipients showed T cell-mediated rejection with 
transplant glomerulitis. Both were C4d negative in peritubular 
capillaries and recovered renal function after anti-rejection ther-
apy consisting of steroid pulse and anti-thymocyte globulin (ATG). 
In the control group, three recipients developed antibody-me-
diated rejection.
 One patient in the sirolimus group succumbed to fungal pneu-
monia (Day 45), and one graft was lost due to BK virus nephrop-
athy (Day 253) during the 12 month study period. In the control 
group, one graft failure occurred due to mixed rejection. No sig-
nificant intergroup difference was found for cytomegalovirus 
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(CMV) infection. However, BKV infection, dyslipidemia, and 
lymphocele rates were significantly higher in the sirolimus group.
 In the sirolimus group, drug-induced pneumonitis occurred 
in 2 patients. Lymphocele occurred in 5 patients (17.9%), and of 
these five, three underwent laparoscopic fenestration and one 
percutaneous catheter drainage. No malignancy was reported 
during the study period.
 In the control group, one case of lymphocele was treated con-
servatively. One patient developed Kaposi’s sarcoma at 7 months 
post-transplant, and was switched from tacrolimus to sirolimus 
with MMF discontinuation. He responded well to treatment and 
remained well at 3 yr post-transplant.
DISCUSSION
Several authors have reported that tacrolimus and sirolimus in 
combination can achieve low rates of acute rejection (8, 9). Fur-
thermore, in a randomized large cohort study, de novo regimens 
containing sirolimus with CNIs were found to be efficacious 
and well tolerated in high risk recipients (10, 11). We decided to 
perform this pilot study in the hope of reducing acute rejection 
rates and improving renal function. Although statistically not 
significant, we found the BPAR rate was higher and mean eGFR 
was lower in the sirolimus group than in the control group. Fur-
thermore, we encountered a high withdrawal rate (28.6%), which 
was attributed to significant increases in BKV infection, lym-
phocele, and dyslipidemia. 
 No therapeutic target ranges have been established for the 
de novo sirolimus/tacrolimus combination (12). In the present 
study, relatively high drug concentrations were maintained than 
in prior studies that adopted de novo tacrolimus plus sirolimus 
regimens (13, 14). However, target drug levels in the present 
study were similar to those reported in previous studies on re-
cipients at high immunological risk (10, 11). But, unlike these 
previous studies, we observed a high incidence of acute rejec-
tion. Although, there is no accepted definition of “high immu-
nological risk” (15), most authors have classified African Amer-
icans as being at high risk, and in such studies the proportion of 
African American exceeded 70% (10, 11). Accordingly, the re-
sults of prior studies should be interpreted with caution as they 
included only a small proportion of other ethnic recipients with 
immunologic risk factors. In the present study, the high incidence 
of acute rejection observed may have been due to underlying 
immunological risk. Nevertheless, the rejection preventing effects 
of sirolimus in this study were inadequate even at a high trough 
level, and sirolimus did not show any advantage in renal func-
tion as compared with the tacrolimus/MMF treated controls. 
 Induction therapy also plays an important role in the preven-
tion of acute rejection. We used basiliximab as an induction ther-
apy and a potent maintenance regimen (tacrolimus plus siroli-
mus). Basiliximab and ATG are widely used for induction ther-
apy in kidney transplantation, and ATG has usually been used 
in high risk or black recipients (16). However, optimal induction 
therapy remains a subject of debate because of the developments 
of more potent immunosuppressive drugs and the risk of over-
immunosuppression. In a recent prospective study, it was shown 
that ATG induction is effective in black recipients, but not effec-
tive in sensitized patients with high PRAs (17). 
 The impact that high drug trough levels have on the develop-
ment of adverse events is an important finding of the present 
study, and has been reported previously in several studies. Siro-
limus related toxicities are known to exhibit dose-dependent 
characteristics (18-20), and a high proportion of recipients in 
present study discontinued sirolimus due to adverse events. As 
mentioned above, the majority of studies on high risk recipients 
have been conducted on African Americans, and previous stud-
ies have shown these patients tend to need higher immunosup-
pressant levels to optimize graft outcomes (10, 21). Thus, the 
high withdrawal and adverse event rates observed in this study 
could be related to the use of relatively high target trough levels 
for non-black recipients. We suggest that efforts be made to de-
termine optimal target drug levels for different ethnicities, be-
cause of the narrow therapeutic window of sirolimus. 
 The high incidence of viral infections encountered in this tri-
al was unexpected, because mTOR inhibitors, like sirolimus, 
are known to have anti-viral effects (22, 23). In this study, a high 
proportion of patients received powerful immunosuppressive 
drugs in addition to mTOR inhibitors. Some of them received 
steroid pulse or ATG treatment for acute rejection. In addition, 
patients with a high PRA titer received rituximab prior to trans-
plantation. The patient’s net state of immunosuppression may 
be attributable to the relatively high incidence of viral infection 
(24, 25).
 Immunosuppressive drugs all have positive and negative char-
acteristics. Recent randomized trials demonstrated comparable 
efficacies and renal functions for de novo CNI/mTOR inhibitor 
and CNI/MMF combinations. Furthermore, similar results have 
been achieved for reduced CNI plus low dose mTOR inhibitor 
therapy. It has been shown that mTOR inhibitors are potent im-
munosuppressants, but in patients at immunological low risk 
Table 3. Acute rejections during the study period 
Rejection factors Sirolimus Control P value
Biopsy proven acute rejection
   TCMR
   AMR
   Mixed rejection
9 (32.1%)
9
0
0
18 (26.1%)
15
  1
  2
0.546
Time to first BPAR, day (median,  
   range) 
61 (5-373) 29 (5-175) 0.455
Anti-rejection treatment
   Antibody therapy*
   Therapeutic plasmapheresis
3 (33.3%)
1 (11.1%)
4 (22.2%)
2 (11.1%)
0.653
> 0.99
*Antithymocyte globulin (ATG). TCMR, T cell mediated rejection; AMR, antibody-medi-
ated rejection; BPAR, Biopsy proven acute rejection.
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(26-28). In the present study, high levels of sirolimus were main-
tained to overcome immunological risk, but contrary to expec-
tation, high trough level of sirolimus did not reduce the incidence 
of acute rejection in our high immunological risk patients. Rath-
er, these high levels were found to be associated with high inci-
dences of adverse events, which contributed to study discon-
tinuation. This was consistent with findings from recent studies, 
in which a higher rate of discontinuation due to adverse events 
occurred in high level mTOR inhibitor group (27, 28).
 The availability of more sensitive tests would allow individu-
als at immunologic risk to be characterized more precisely. How-
ever, traditional risk factors, such as, high PRA and poor HLA 
matching remain problematic and optimal immunosuppres-
sive strategies for recipients at high immunologic risk are still 
being investigated (29). Furthermore, because of their small 
numbers and heterogeneous degrees of risk, patients at high 
immunologic risk have been excluded from clinical trials. Ac-
cordingly, special efforts are needed to identify proper immu-
nosuppression strategies for these recipients.
 Several limitations of our study require consideration. First, it 
was a single arm study conducted on a small population, and 
the trial was terminated prematurely due to high rates of acute 
rejection and withdrawal due to adverse events. Therefore, we 
retrospectively compared the results of this pilot study with those 
of a nonrandomized contemporaneous control group. Second, 
the study is limited by its 12-month follow-up, which prevents 
predictions of long-term outcomes. Despite the high rate of dis-
continuation encountered, we are continuing to collate follow-
up data to gain access to long-term outcomes. Third, we did not 
routinely measure donor-specific anti-HLA antibodies during 
the study period, because the clinical use of solid phase test for 
antibody detection was not well established during the design 
phase of this study. Further randomized studies across ethnici-
ties with longer follow-ups are required to prove the effective-
ness of immunosuppressive strategies in recipients at high im-
munological risk.
 We conclude that the tacrolimus/sirolimus combination reg-
imen may not be an ideal choice for recipients at high immu-
nologic risk. Further investigations should be conducted to de-
termine optimal target blood levels of tacrolimus and sirolimus 
to reduce side effects.
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